
Thymosin beta-4
Also called Tβ4
- Evidence
- Limited research
- Class
- Actin-regulating peptide
Thymosin beta-4 belongs to the Actin-regulating peptide class. This library groups it under bones & muscles. Its source category is Not FDA-approved.
At a glance
| Compound class | Actin-regulating peptide |
|---|---|
| Body system | Bones & muscles |
| Use or research focus | Wound/tissue healing |
| Regulatory status | Not FDA-approved |
| Source evidence rating | Limited research |
How does Thymosin beta-4 work?
Tissue repair, anti-inflammatory, angiogenesis.
The source catalog maps this mechanism to Joints / Connective tissue, Heart / Cardiovascular, Skin. A biological mechanism describes how a compound interacts with the body; it does not by itself prove a clinical benefit.
What does the evidence tell us?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Use the Citations tab to examine the underlying sources. Look for human studies, a relevant comparison group, meaningful outcomes, and adequate follow-up. An ingredient, approved drug, and compounded preparation may have different evidence.
Safety and considerations
For an unapproved use or compound, safety and effectiveness may be uncertain. Products sold for research are not a substitute for prescribed care. Do not infer a human dose, injection protocol, or treatment recommendation from preclinical research.
This library is educational and does not provide dosing or treatment instructions. A listing here does not indicate that Peppy offers the compound.
Common questions
What is Thymosin beta-4?
Thymosin beta-4 belongs to the Actin-regulating peptide class. This library groups it under bones & muscles. Its source category is Not FDA-approved. Its recorded use or research focus is: Wound/tissue healing.
Is Thymosin beta-4 FDA-approved?
The catalog records: Not FDA-approved. Check the current product-specific regulatory information in the source links; a source category does not establish approval for every use or formulation.
How strong is the research?
The source catalog rates the evidence as limited. Laboratory and animal findings cannot establish benefits or safety in people. Small or early studies may raise useful research questions without supporting routine clinical use.
Where can I read the research?
The Citations tab contains 14 reference links from the source dataset. The original research guide provides additional context. These links are a starting point for reading the evidence.
More for bones & muscles
Factual catalog fields and citation links are adapted from Superpower’s Thymosin beta-4 guide and the public dataset linked in the reference post. Peppy’s explanations are educational; this page does not represent an independent clinical review of every linked study.
Sources & further reading
References associated with Thymosin beta-4 in the source dataset. Open a source to review its study design, population, limitations, and date.
- 01regenerative propertiesdoi.org
- 02venous-ulcer studydoi.org
- 03Phase III in dry eyeclinicaltrials.gov
- 04Phase III neurotrophic keratopathy trialpubmed.ncbi.nlm.nih.gov
- 0543-amino-acid peptidepubmed.ncbi.nlm.nih.gov
- 06active site for actin bindingpubmed.ncbi.nlm.nih.gov
- 072025 cardiac RCTpubmed.ncbi.nlm.nih.gov
- 08FDA has identified no human exposure datafda.gov
- 09Phase III trial in neurotrophic keratopathyclinicaltrials.gov
- 10Annals of the New York Academy of Sciencespubmed.ncbi.nlm.nih.gov
- 11Journal of Cellular and Molecular Medicinepubmed.ncbi.nlm.nih.gov
- 1242% increase in reepithelializationpubmed.ncbi.nlm.nih.gov
- 13announced on April 15, 2026statnews.com
- 14voted 8-6 to recommend TB-500statnews.com





